Neo-adjuvant immunotherapy in bladder cancer. Complete pathological response in bladder wall is related with the PDL1 status and opens opportunities to understand biological mechanism of action.

More

Perhaps Even up to Half the Amount?

More

Announcing HistoGeneX's new partnership with the BluePrint 2 Initiative.

More

The differential expression of commercial PD-L1 antibodies is well known but poorly understood. Our epitope mapping of four antibodies reveal that antigen binding might be depending on PD-L1 conformation or isoform expression. For example, the presence of the dominant isoform 2 may impact SP142 binding. 

More

HistoGeneX’s Founder and Head Pathologist, Mark Kockx is interviewed by CAP Today for his histopathology perspectives of inflammation within the tumor microenvironment.

More